SCHEMBL31627634

SCHEMBL31627634

COC(=O)Nc1cc(Cl)c(CO)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 1/20 0.44
▸ JAK1 P23458 1/20 0.44
▸ TYK2 P29597 1/20 0.44
▸ AAK1 Q2M2I8 6/20 0.39
▸ TSHR P16473 1/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ TP53 P04637 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2D6 P10635 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ FGFR4 P22455 1/20 0.38
▸ ROCK2 O75116 1/20 0.38
▸ NR2C2 P49116 1/20 0.38
▸ MAP2K1 Q02750 1/20 0.38
▸ HIPK4 Q8NE63 1/20 0.38
▸ CLK4 Q9HAZ1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31627729 0.87 JAK2 (0.43) JAK2JAK1TYK2AAK1RAB9A
SCHEMBL17143267 0.84 PTK2 (0.50) JAK2JAK1TYK2AAK1CYP1A2
SCHEMBL31627890 0.78 JAK2 (0.46) JAK2JAK1TYK2AAK1RAB9A
SCHEMBL31627741 0.78 JAK2 (0.46) JAK2JAK1TYK2AAK1RAB9A
SCHEMBL30755999 0.75 PTK2 (0.46) JAK2JAK1TYK2RAB9ACYP3A4
SCHEMBL3609970 0.74 PDXK (0.38) SMN1; SMN2FGFR4NNMTMEN1KMT2A
SCHEMBL31627881 0.74 CHEK1 (0.46) JAK2JAK1TYK2RAB9ANPC1
SCHEMBL31627922 0.74 JAK2 (0.42) JAK2JAK1TYK2AAK1RAB9A
SCHEMBL27441737 0.71 AAK1 (0.42) JAK2JAK1TYK2AAK1CYP3A4
SCHEMBL992612 0.70 PDXK (0.44) RAB9ANPC1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236609-A1 VPS34 INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2025-07-24 — — US disclosed
WO-2025129019-A1 VPS34 INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2025-06-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236609-A1 VPS34 INHIBITORS AND METHODS OF USE THEREOF VPS35, VPS28, VPS26B JAK2 1725/4885JAK1 690/4885TYK2 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback